Product nameAnti-TAF9 antibody [EPR12075(B)]
See all TAF9 primary antibodies
DescriptionRabbit monoclonal [EPR12075(B)] to TAF9
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Cow, Orangutan
Synthetic peptide corresponding to residues in Human TAF9, (Uniprot ID: Q16594)
- HeLa, A431, MCF-7 and K562 cell lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
- HeLa nuclear extract lysate (ab14655)
- K562 nuclear extract lysate (ab14851)
- MCF7 nuclear extract lysate (ab14860)
- HeLa whole cell lysate (ab150035)
- HeLa nuclear extract lysate (ab150036)
- HeLa whole cell lysate (ab29545)
- MCF7 whole cell lysate (ab3871)
- A431 whole cell lysate (ab7909)
- K562 whole cell lysate (ab7911)
Our Abpromise guarantee covers the use of ab169784 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 29 kDa.|
For unpurified use at 1/100 - 1/250
RelevanceTAF9 functions as a component of the DNA-binding general transcription factor complex TFIID and the regulatory transcription complex SAGA. Binding of TFIID to a promoter (with or without TATA element) is the initial step in pre-initiation complex (PIC) formation. TFIID plays a key role in the regulation of gene expression by RNA polymerase II through different activities such as transcription activator interaction, core promoter recognition and selectivity, TFIIA and TFIIB interaction, chromatin modification (histone acetylation by TAF1), facilitation of DNA opening and initiation of transcription. SAGA influences RNA polymerase II transcriptional activity through different activities such as TBP interaction (SPT3 and SPT8) and promoter selectivity, interaction with transcription activators (GCN5, ADA2, ADA3, and TRA1), and chromatin modification through histone acetylation (GCN5).
- TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kDa antibody
- MGC:1603 antibody
- MGC:3647 antibody
All lanes : Anti-TAF9 antibody [EPR12075(B)] (ab169784) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : A431 cell lysate
Lane 3 : MCF7 cell lysate
Lane 4 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 29 kDa
Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling TAF9 with purified ab169784 at 1/500. Cells were fixed with 4% Paraformaldehyde. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (ab150077) at 1/1000 dilution was used as the secondary antibody. Nuclei couterstained with DAPI (blue).
Secondary Only Control: PBS was used instead of the primary antibody as the negative control.
Immunofluorescence analysis of MCF7 cells, labeling TAF9 using ab169784 at a 1/100 dilution.